ZIOP
Income statement / Annual
Last year (2024), ZIOPHARM Oncology, Inc.'s total revenue was $10.00 K,
and the percentage change from the previous year is not available.
In 2024, ZIOPHARM Oncology, Inc.'s net income was -$4.68 M.
See ZIOPHARM Oncology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2024 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$10.00 K |
$0.00 |
$0.00 |
$146.00 K |
$6.39 M |
$6.86 M |
$4.33 M |
$1.37 M |
$800.00 K |
$800.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$146.00 K
|
$6.39 M
|
$6.86 M
|
$4.33 M
|
$1.37 M
|
$800.00 K
|
$800.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$362.00 K
|
$52.70 M
|
$38.33 M
|
$34.13 M
|
$45.08 M
|
$157.79 M
|
$106.79 M
|
$32.71 M
|
$42.85 M
|
$83.45 M
|
| General & Administrative Expenses |
$4.46 M
|
$27.67 M
|
$19.53 M
|
$19.92 M
|
$14.80 M
|
$14.38 M
|
$17.65 M
|
$12.17 M
|
$15.66 M
|
$19.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.46 M
|
$27.67 M
|
$19.53 M
|
$19.92 M
|
$14.80 M
|
$14.38 M
|
$17.65 M
|
$12.17 M
|
$15.66 M
|
$19.52 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.82 M
|
$80.36 M
|
$57.86 M
|
$54.05 M
|
$59.88 M
|
$172.17 M
|
$124.43 M
|
$44.87 M
|
$58.51 M
|
$102.97 M
|
| Cost And Expenses |
$0.00
|
$80.36 M
|
$57.86 M
|
$54.05 M
|
$59.88 M
|
$172.17 M
|
$124.43 M
|
$44.87 M
|
$58.51 M
|
$102.97 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.13 M
|
$629.00 K
|
$575.00 K
|
$369.00 K
|
$290.00 K
|
$357.00 K
|
$462.00 K
|
$738.00 K
|
$658.00 K
|
| EBITDA |
-$4.81 M |
-$78.85 M |
-$117.17 M |
-$52.54 M |
-$53.95 M |
-$165.01 M |
-$119.73 M |
-$31.32 M |
-$56.37 M |
-$95.47 M |
| EBITDA Ratio |
-481.2
|
0
|
0
|
-359.88
|
-8.44
|
-24.05
|
-27.64
|
-22.81
|
-70.46
|
-119.34
|
| Operating Income Ratio |
-481.2
|
0
|
0
|
-363.82
|
-8.5
|
-24.09
|
-27.72
|
-23.15
|
-71.38
|
-120.17
|
| Total Other Income/Expenses Net |
$133.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$4.68 M
|
-$79.98 M
|
-$117.80 M
|
-$53.12 M
|
-$54.32 M
|
-$165.30 M
|
-$120.09 M
|
-$31.78 M
|
-$57.11 M
|
-$96.13 M
|
| Income Before Tax Ratio |
-467.9
|
0
|
0
|
-363.82
|
-8.5
|
-24.09
|
-27.72
|
-23.15
|
-71.38
|
-120.17
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$4.68 M
|
-$79.98 M
|
-$117.80 M
|
-$53.12 M
|
-$54.32 M
|
-$165.30 M
|
-$120.09 M
|
-$31.78 M
|
-$57.11 M
|
-$96.13 M
|
| Net Income Ratio |
-467.9
|
0
|
0
|
-363.82
|
-8.5
|
-24.09
|
-27.72
|
-23.15
|
-71.38
|
-120.17
|
| EPS |
-2.92 |
-0.38 |
-0.7 |
-0.37 |
-0.4 |
-1.27 |
-0.96 |
-0.31 |
-0.66 |
-1.22 |
| EPS Diluted |
-2.92 |
-0.38 |
-0.7 |
-0.37 |
-0.4 |
-1.27 |
-0.96 |
-0.31 |
-0.66 |
-1.22 |
| Weighted Average Shares Out |
$1.60 B
|
$209.64 M
|
$167.95 M
|
$143.71 M
|
$136.94 M
|
$130.39 M
|
$125.42 M
|
$101.13 M
|
$85.94 M
|
$78.55 M
|
| Weighted Average Shares Out Diluted |
$1.60 B
|
$209.64 M
|
$167.95 M
|
$143.71 M
|
$136.94 M
|
$130.39 M
|
$125.42 M
|
$101.13 M
|
$85.94 M
|
$78.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
